GBG

PinkOctober – Research Brings Hope: #INSEMA Study #GBG75

📖 Most recent results have been published in #NEJM: www.nejm.org/doi/full/10....

Exciting news: the latest INSEMA data will be presented as an Oral Presentation at the San Antonio Breast Cancer Symposium #SABCS2025 this December.

#NeoRad study #GBG116: phase III trial investigating whether #preoperative radiotherapy can improve disease-free survival compared to #postoperative #radiotherapy after #neoadjuvant #chemotherapy in patients with high-risk early breast cancer.
👉 More information: www.gbg.de/en/trials/neorad

#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery

Today at the #DGHO Annual Meeting 2025 #Cologne: #GBG presents exciting new research on combination therapy for #BRCA-mutated #breastcancer! Proud to share the #ELEMENT study #GBG114 — a randomized phase II trial exploring whether adding the oral #SERD #elacestrant to the #PARP inhibitor #olaparib.

Published in #BCR this year introduces a powerfulprediction model for pathological complete response in #HER2-negative #breastcancer, developed using data from more than 1,100 pts: observational Hannover Breast Cancer Study and randomized #GeparSepto #GBG69 and #GeparOcto #GBG84 #clinicaltrials.

In this #BreastCancerAwarenessMonth, we are excited to share that #GBG will have a strong scientific presence at the San Antonio Breast Cancer Symposium #SABCS2025 — one of the most important international meetings in breast cancer research. 💡

GeparPiPPa Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib

#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...

#BreastCancerAwarenessMonth2025: This October, as we raise awareness for #breastcancer and highlight the importance of long-term patient care, we invite all former study participants to take part in the #GBG071 #Registry

👉 Learn more and register here: www.gbg.de/en/trials/re...

#Flamingo-01 #GBG111: a global phase III, randomized, placebo-controlled study investigating the GLSI-100 immunotherapy in HLA-A*02-positive and HER2/neu-positive breast cancer patients who remain at high risk of #recurrence after completing both #neoadjuvant and #adjuvant standard therapy.

#PinkOctober: The study reveals that luminal breast tumors can dynamically change under #neoadjuvant #chemotherapy - with aggressive #Luminal B tumors often transitioning into a less aggressive Luminal A type.

Read full publication here: www.cell.com/cancer-cell/...

#PinkOctober | #ESMO2025

#BMBC registry #GBG79 as poster presentation: The results highlight the importance of retesting #HER2 status in #metastatic sites and open the door to new, targeted treatment opportunities — even for patients previously classified as HER2-negative.

#ESMO2025 #GBG presented long-term results from #GeparNuevo trial #GBG96 providing new insights into the role of immunotherapy in early #TNBC - survival benefit for #PD-L1 inhibitor was showed.
This is the only trial with benefit in combination with dose-dense chemotherapy without carboplatin!

#DESTINY-Breast05 trial #GBG103 at #ESMO2025: T-DXd as a potential new #SOC?

The phase III study demonstrated statistically significant and clinically meaningful improvement in #IDFS #DFS with #T-DXd vs #T-DM1 in pts with high-risk #HER2-positive eBC who had residual invasive disease.

#GBG at #ESMO2025: As one of the leading research groups in breast cancer, we are proud to contribute to several presentations and discussions that will shape the future of oncology research.
We’re looking forward to inspiring sessions, great scientific exchange at #ESMO25

#BreastCancerAwarenessWeek for Men with #BreastCancer 💙
As part of this awareness week, the #GBG would like to highlight a crucial topic for all individuals affected by breast cancer: molecular and genetic testing.
Learn more: www.gbg.de/news/detail/...
Workshop-Link: www.youtube.com/watch?v=_tIP...

#PinkOctober Spotlight: The #ETERNITY-B #Registry #GBG107 – a prospective and retrospective follow-up project dedicated to understanding the long-term #safety and #efficacy of #treatments used in #GBG #clinicaltrials for early-stage #breastcancer

👉 Learn more: www.gbg.de/en/trials/et...

#LOBSTER trial #GBG118 for pts with #lobular #breastcancer: It investigates whether the combination of #capivasertib + #fulvestrant can achieve a stronger therapeutic effect than fulvestrant alone – aiming to reduce #recurrence risk and improve quality of life.
👉 www.gbg.de/en/trials/lo...

#PinkOctober2025: #Leptomeningeal #metastases #LM remain one of the most severe complications in breast cancer, associated with a markedly poorer #prognosis than brain metastases without LM.

This large #registry analysis highlights an urgent unmet clinical need: pmc.ncbi.nlm.nih.gov/articles/PMC...

#PinkOctober 2025 | Spotlight on BMBC Study – Understanding Brain #Metastases in Breast Cancer #BMBC
📰 What’s next: We’re excited to announce that new analyses from the BMBC registry will be presented at #ESMO25 and #SABCS25. Stay tuned for more details in the coming days!
www.gbg.de/en/trials/bmbc

Hot from the Press | #BreastCancerScreening Works – New Data Show Significant Reduction in Mortality.
Findings clearly demonstrate: Mammography screening saves lives – and remains a key pillar in reducing #breastcancer mortality in Germany: ZEBra-MSP project doris.bfs.de/jspui/handle...

#PinkOctober | Understanding #BreastCancer in #Pregnancy
#BCP, #GBG29: With the trend toward later motherhood, the incidence of breast cancer during pregnancy is slowly increasing. Yet, data on how the disease and its treatment affect both mother and child remain limited. BCP aims to fill this gap.

#PinkOctober | #Publication on Breast Cancer Diagnosed During #Pregnancy in #npjBreastCancer: Findings provide important insights into the biology of pregnancy-associated breast cancer #PrBC and may guide future strategies for patient care.
👉 pmc.ncbi.nlm.nih.gov/articles/PMC...

#PinkOctober: #Cambria-2 Trial #GBG115: international phase III clinical trial exploring whether #SERD #Camizestrant can offer better protection against recurrence than standard adjuvant endocrine therapy in pts with early-stage ER+/HER2- breast cancer www.gbg.de/en/trials/ca...

#PinkOctober: we highlight the #Cambria-1 #GBG110 trial – a study that offers new perspectives for pts with early-stage ER+/HER2- #breastcancer
Goal: Compare invasive breast cancer-free survival between pts receiving #Camizestrant and those continuing on standard therapy 👉 www.gbg.de/en/trials/ca...

In The Lancet Regional Health – Europe: important real-world insights into the prevalence and prognosis of pts with early ER+/HER2- breast cancer who may be eligible for adjuvant CDK4/6 inhibitors: #monarchE and #NATALEE compared to #PANTHER trial #GBG53
www.sciencedirect.com/science/arti...

Pink October: #GBG highlight a special offer: interactive #workshops “Brustkrebs kompakt erklärt”
These online workshops are designed to provide scientifically sound, practice-oriented knowledge at the highest level, aligned with the latest state of #BreastCancer research: www.workshops.gbg.events

Spotlight on the #MOMENTUM study #GBG 108 – a prospective, non-interventional, translational registry study.

🧬 By analyzing #tumor tissue and #ctDNA, we seek to uncover how tumors evolve over time – and how therapies can be made more precise and effective.

👉 www.gbg.de/studien/mome...

Progress in breast cancer (BC) research: #TAXIS - phase III trial exploring innovative treatment strategies for pts with clinically node-positive BC. The study evaluates tailored axillary surgery +/- lymph node dissection, followed by radiotherapy.
Publication: www.ejcancer.com/article/S095...
#GBG

Driving Innovation in Breast Cancer Research!

At #GBG, we cover the full spectrum of breast cancer #treatment – always striving to improve outcomes for patients.

Our strength lies in investigator-initiated, academically driven trials, complemented by service studies for our partners.
www.gbg.de

📰 Final survival results of #PENELOPE-B trial: While routine adjuvant palbociclib cannot be recommended for all HR+/HER2− early breast cancers (BC), the results point to importance of histological subtypes. For lobular BC CDK4/6 inhibition hold new promise: www.annalsofoncology.org/article/S092...